Fi3 Financial Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$348K Buy
12,391
+2,381
+24% +$63.4K 0.1% 120
2025
Q4
$249K Buy
10,010
+285
+3% +$7.19K 0.08% 151
2025
Q3
$248K Buy
9,725
+1,243
+15% +$30.7K 0.08% 123
2025
Q2
$206K Buy
8,482
+404
+5% +$9.42K 0.07% 161
2025
Q1
$205K Sell
8,078
-4,615
-36% -$121K 0.08% 127
2024
Q4
$337K Buy
+12,693
New +$344K 0.13% 67
2023
Q3
Sell
-5,512
Closed -$202K 77
2023
Q2
$202K Buy
+5,512
New +$215K 0.11% 65
2023
Q1
Sell
-5,290
Closed -$271K 81
2022
Q4
$271K Buy
+5,290
New +$254K 0.16% 49

Other funds holding PFE

Fi3 Financial Advisors's PFE Position: Q1 2026 in Review

Fi3 Financial Advisors increased its Pfizer (PFE) stake by 24% in Q1 2026, buying an estimated $63.4K and bringing the position to 12,391 shares worth $348K. The position accounts for 0.1% of the portfolio, ranked #120.

Fi3 Financial Advisors first reported a position in PFE in Q4 2022 and has held it in 8 quarters since. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Fi3 Financial Advisors held 12,391 shares of Pfizer worth $348K as of Q1 2026.
  • Fi3 Financial Advisors bought 2,381 Pfizer shares in Q1 2026, an estimated $63.4K.
  • Pfizer made up 0.1% of Fi3 Financial Advisors's portfolio in Q1 2026, its #120 holding.
  • Fi3 Financial Advisors first reported a position in Pfizer in Q4 2022 and has held it in 8 quarters since.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Fi3 Financial Advisors's 13F filing for Q1 2026, filed 7 May 2026.